InflaRx publishes Phase 1 izicopan data, backing Capital Markets Day plans for AAV
Peer-reviewed Phase 1 results support safety and dosing seen earlier, as InflaRx proceeds toward 2027 Phase 2 trials with peak sales estimated at $1.5-2.0 billion.
SEC filing (3)